March 2024 : The US FDA approved a label expansion for WEGOVY based on a supplemental New Drug Application (sNDA) for the indication of reducing risks of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack (myocardial infarction), or non-fatal stroke in adults with either overweight or obesity and established CVD
Increasingly, were learning GLP-1 RAs have an important role in managing a common set of chronic diseases called CKM, or cardiovascular-kidney-metabolic syndrome [archived link]
Results showed that liraglutide provided glycemic control comparable to or better than these alternatives, with additional benefits such as reduced weight gain and fewer hypoglycemic episodes (36)
Why did I treat cocaine a certain way
Quick Answer: Most people notice appetite suppression within days to two weeks of starting GLP-1 treatment, blood glucose improvements within 24 weeks, and meaningful weight loss over 36 months
Illustration by Donnisa Edmonds